Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peptide-based blood coagulant - Haemostatix

Next Previous
Drug Profile

Peptide-based blood coagulant - Haemostatix

Alternative Names: Haemostasis therapeutic - Haemostatix; Haemostat topical - Haemostatix; PeproStat; PeproStat Liquid; Peptide-based antihaemorrhagic - Haemostatix

Latest Information Update: 11 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Haemostatix
  • Developer Boryung Pharmaceutical; Haemostatix
  • Class Antihaemorrhagics; Peptides
  • Mechanism of Action Fibrin stimulants; Fibrinogen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Surgical blood loss

Most Recent Events

  • 10 Aug 2021 Phase-II clinical trials in Surgical blood loss in South Korea (Topical, Liquid) (Boryung Pharmaceutical pipeline, August 2021)
  • 05 Mar 2021 No development reported - Phase-II for Surgical blood loss (Prevention) in Serbia, United Kingdom, Croatia, Bosnia-Herzegovina, Poland (Topical)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Surgical-blood-loss(Prevention) in United Kingdom (Topical, Paste)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top